CN114113627A - Alzheimer's disease detection kit based on magnetic particle luminescence method - Google Patents
Alzheimer's disease detection kit based on magnetic particle luminescence method Download PDFInfo
- Publication number
- CN114113627A CN114113627A CN202111241752.3A CN202111241752A CN114113627A CN 114113627 A CN114113627 A CN 114113627A CN 202111241752 A CN202111241752 A CN 202111241752A CN 114113627 A CN114113627 A CN 114113627A
- Authority
- CN
- China
- Prior art keywords
- alzheimer
- detection
- solution
- microbeads
- magnetic particle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 35
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 11
- 238000002796 luminescence method Methods 0.000 title claims abstract description 11
- 239000006249 magnetic particle Substances 0.000 title claims abstract description 11
- 239000000243 solution Substances 0.000 claims abstract description 32
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 25
- 239000011325 microbead Substances 0.000 claims abstract description 23
- 239000004005 microsphere Substances 0.000 claims abstract description 19
- 239000007853 buffer solution Substances 0.000 claims abstract description 18
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 claims abstract description 11
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims abstract description 11
- 239000011534 wash buffer Substances 0.000 claims abstract description 10
- 238000002474 experimental method Methods 0.000 claims abstract description 8
- 239000012224 working solution Substances 0.000 claims abstract description 8
- 239000004793 Polystyrene Substances 0.000 claims abstract description 7
- 229920002223 polystyrene Polymers 0.000 claims abstract description 7
- 239000007850 fluorescent dye Substances 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims abstract 2
- 230000004913 activation Effects 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 8
- 239000011248 coating agent Substances 0.000 claims description 6
- 238000000576 coating method Methods 0.000 claims description 6
- 230000003213 activating effect Effects 0.000 claims description 5
- 239000011259 mixed solution Substances 0.000 claims description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 3
- CCMKPCBRNXKTKV-UHFFFAOYSA-N 1-hydroxy-5-sulfanylidenepyrrolidin-2-one Chemical compound ON1C(=O)CCC1=S CCMKPCBRNXKTKV-UHFFFAOYSA-N 0.000 claims description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 239000011324 bead Substances 0.000 claims 2
- 108010004729 Phycoerythrin Proteins 0.000 claims 1
- 108010090804 Streptavidin Proteins 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000002331 protein detection Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 28
- 102000004169 proteins and genes Human genes 0.000 abstract description 28
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000011550 stock solution Substances 0.000 description 24
- 230000000087 stabilizing effect Effects 0.000 description 12
- 229920001213 Polysorbate 20 Polymers 0.000 description 10
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 10
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 10
- 239000012535 impurity Substances 0.000 description 8
- 239000008363 phosphate buffer Substances 0.000 description 8
- 238000007865 diluting Methods 0.000 description 7
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000011146 sterile filtration Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
The invention discloses an Alzheimer's disease detection kit based on a magnetic particle luminescence method, which comprises: a plurality of sealed reagent bottles which are respectively filled with capture microsphere mixed liquor, detection antibody, SA-PE, experiment buffer solution, washing buffer solution and working solution, and a kit which separates and integrally packages the reagent bottles; the micro-beads are polystyrene micro-beads dyed by different fluorescent dyes and coded; the capture microsphere mixture contains microbeads conjugated with human Abeta 1-42 antibody and microbeads conjugated with human p-tau-181 antibody. The invention solves the problem that when detecting the Abeta 1-42 and the p-tau-181 proteins in a sample, two detection reagents are needed to be used independently to detect the Abeta 1-42 and the p-tau-181 proteins respectively, shortens the detection time, thereby improving the detection efficiency, provides an effective laboratory detection means for Alzheimer patients, and has important significance for diagnosis and further treatment.
Description
Technical Field
The invention relates to an Alzheimer's detection kit based on a magnetic particle luminescence method, belongs to the technical field of detection reagents, and discloses a detection kit capable of simultaneously detecting two proteins of Abeta 1-42 and p-tau-181 in a sample in a micropore.
Background
The protein A beta 1-42 and the protein p-tau-181 are common index proteins of Alzheimer patients, however, with the progress of medical treatment level, the protein A beta 1-42 and the protein p-tau-181 can be detected by the existing detection reagent and then further treated, however, when the protein A beta 1-42 and the protein p-tau-181 in a sample are detected, the protein A beta 1-42 and the protein p-tau-181 need to be detected by two detection reagents separately, so that the detection time is increased, and the detection efficiency is reduced.
Disclosure of Invention
The technical problem to be solved by the invention is as follows: provides an Alzheimer's disease detection kit based on a magnetic particle luminescence method, which solves the problem that when detecting Abeta 1-42 and p-tau-181 protein in a sample, two detection reagents are required to be used for separately detecting Abeta 1-42 and p-tau-181 protein.
The technical problem to be solved by the invention is realized by adopting the following technical scheme:
an Alzheimer's disease detection kit based on a magnetic particle luminescence method comprises a capture microsphere mixed solution, a detection antibody, SA-PE, an experiment buffer solution, a washing buffer solution and a working solution,
(1) capturing microsphere mixed liquor: the suspension contains identifiable polystyrene microbeads, and the polystyrene microbeads are respectively coated with the following antibodies: anti-human Abeta 1-42 antibody, anti-human p-tau-181 antibody;
(2) detecting an antibody: diluting the stock solution with protein stabilizing solution 62.5 times under the condition that the concentration of the stock solution is 0.5mg/mL to ensure that the concentration is 0.8 mu g/mL;
(3) and SA-PE: diluting the stock solution with protein stabilizing solution 50 times under the condition that the concentration of the stock solution is 1mg/mL to ensure that the concentration is 2 mug/mL;
(4) working fluid: diluting the stock solution with protein stabilizing solution 6.7 times under the condition that the concentration of the stock solution is 40.6mg/mL to ensure that the concentration is 0.6 mg/mL;
(5) experiment buffer solution: adding 50g BSA, 1mL Tween-20, 3mL Proclin300 and 0.5mL RPE2520 into 1000mL of phosphate buffer, stirring for more than 30min, and performing sterile filtration with the diameter of at least 0.45 μm after the solution is clear and free of impurities;
(6) washing buffer solution: 5mL Tween-20, 3mL Proclin300 and 0.3mL RPE2520 were added to 1000mL of phosphate buffer, stirred for more than 30min, and sterile filtered to at least 0.45 μm after the solution was clear and free of impurities.
As a preferred example, the production process of the kit mainly comprises the following steps:
preparing an activation buffer solution, wherein the main components of the activation buffer solution comprise: namely 8.0g/L NaCl reagent, 2.9g/L Na2HPO4·12H2O reagent, 2.4g/L KCl reagent, 2.4g/L KH reagent2PO4Reagent, 0.5g/L Tris reagent, 0.5mL/L Tween20 reagent, 0.5g/L SodiumAzide reagent.
② activation and coating of microspheres, adding 1mL of microspheres with specific numbers into a 1.5mL centrifuge tube, adding 5-50uLEDC (1-ethyl- (3-dimethylaminopropyl) carbodiimide hydrochloride) and 5-50uLSuLfo-NHS (N-hydroxy thiosuccinimide), adding 10-100ug of specific antibody, vortex mixing for 30 seconds, ultrasonic mixing for 30 seconds, and shaking for overnight at 2-8 ℃.
Preparing a detection antibody: when the concentration of the stock solution was 0.5mg/mL, the stock solution was diluted 62.5-fold with the protein stabilizing solution to a concentration of 0.8. mu.g/mL.
Preparing SA-PE: when the concentration of the stock solution was 1mg/mL, the stock solution was diluted 50-fold with the protein stabilizing solution to a concentration of 2. mu.g/mL.
Preparing working solution: when the concentration of the stock solution was 40.6mg/mL, the stock solution was diluted 6.7-fold with the protein stabilizing solution to a concentration of 0.6 mg/mL.
Preparing an experimental buffer solution: 50g BSA, 1mL Tween-20, 3mL Proclin300 and 0.5mL RPE2520 were added to 1000mL of phosphate buffer, stirred for more than 30min, and sterile filtered to at least 0.45 μm after the solution was clear and free of impurities.
Preparing a washing buffer solution: 5mL Tween-20, 3mL Proclin300 and 0.3mL RPE2520 were added to 1000mL of phosphate buffer, stirred for more than 30min, and sterile filtered to at least 0.45 μm after the solution was clear and free of impurities.
The invention has the beneficial effects that: the method comprises the steps of capturing microsphere mixed liquor, detecting antibodies, SA-PE, experiment buffer solution, washing buffer solution and working solution, wherein the production process comprises the steps of preparing activation buffer solution, activating and coating microspheres, preparing detection antibodies, preparing SA-PE, preparing working solution, preparing experiment buffer solution and preparing washing buffer solution for production, so that the problem that when detecting Abeta 1-42 and p-tau-181 proteins in a sample, six detection reagents are required to be used for separately detecting Abeta 1-42 and p-tau-181 proteins is solved, the detection time is shortened, and the detection efficiency is improved.
Detailed Description
In order to make the technical means, the original characteristics, the achieved purpose and the efficacy of the invention easily understood, the invention is further described with reference to the following embodiments.
An Alzheimer's disease detection kit based on a magnetic particle luminescence method comprises a capture microsphere mixed solution, a detection antibody, SA-PE, an experiment buffer solution, a washing buffer solution and a working solution,
(1) capturing microsphere mixed liquor: the suspension contains identifiable polystyrene microbeads, and the polystyrene microbeads are respectively coated with the following antibodies: anti-human Abeta 1-42 antibody, anti-human p-tau-181 antibody;
(2) detecting an antibody: diluting the stock solution with protein stabilizing solution 62.5 times under the condition that the concentration of the stock solution is 0.5mg/mL to ensure that the concentration is 0.8 mu g/mL;
(3) and SA-PE: diluting the stock solution with protein stabilizing solution 50 times under the condition that the concentration of the stock solution is 1mg/mL to ensure that the concentration is 2 mug/mL;
(4) working fluid: diluting the stock solution with protein stabilizing solution 6.7 times under the condition that the concentration of the stock solution is 40.6mg/mL to ensure that the concentration is 0.6 mg/mL;
(5) experiment buffer solution: adding 50g BSA, 1mL Tween-20, 3mL Proclin300 and 0.5mL RPE2520 into 1000mL of phosphate buffer, stirring for more than 30min, and performing sterile filtration with the diameter of at least 0.45 μm after the solution is clear and free of impurities;
(6) washing buffer solution: 5mL Tween-20, 3mL Proclin300 and 0.3mL RPE2520 were added to 1000mL of phosphate buffer, stirred for more than 30min, and sterile filtered to at least 0.45 μm after the solution was clear and free of impurities.
The production process of the kit mainly comprises the following steps:
preparing an activation buffer solution, wherein the main components of the activation buffer solution comprise: namely 8.0g/L NaCl reagent, 2.9g/L Na2HPO4·12H2O reagent, 2.4KCl reagent of g/L, KH of 2.4g/L2PO4Reagent, 0.5g/L Tris reagent, 0.5mL/L Tween20 reagent and 0.5g/L SodiumAzide reagent;
② activation and coating of microspheres, adding 1mL of microspheres with specific numbers into a 1.5mL centrifuge tube, adding 5-50uLEDC (1-ethyl- (3-dimethylaminopropyl) carbodiimide hydrochloride) and 5-50uLSuLfo-NHS (N-hydroxy thiosuccinimide), adding 10-100ug of specific antibody, vortex mixing for 30 seconds, ultrasonic mixing for 30 seconds, and shaking for overnight at 2-8 ℃.
When the detection kit is produced, shaking tables of 6 antibody bottles are required to be placed at the same time, microspheres with different numbers are respectively coated, and the steps are as follows:
1) washing: performing suction filtration washing, and transferring the washed microbeads to an activation buffer solution;
2) quality control: verifying quality by using a quality control panel;
3) mixing multiple coated microbeads, washing residual microbeads on the wall of the bottle with a small amount of activating buffer solution, mixing, diluting to constant volume with the activating buffer solution, and packaging after inspection is qualified.
Preparing a detection antibody: when the concentration of the stock solution was 0.5mg/mL, the stock solution was diluted 62.5-fold with the protein stabilizing solution to a concentration of 0.8. mu.g/mL.
Preparing SA-PE: when the concentration of the stock solution was 1mg/mL, the stock solution was diluted 50-fold with the protein stabilizing solution to a concentration of 2. mu.g/mL.
Preparing working solution: when the concentration of the stock solution was 40.6mg/mL, the stock solution was diluted 6.7-fold with the protein stabilizing solution to a concentration of 0.6 mg/mL.
Preparing an experimental buffer solution: 50g BSA, 1mL Tween-20, 3mL Proclin300 and 0.5mL RPE2520 were added to 1000mL of phosphate buffer, stirred for more than 30min, and sterile filtered to at least 0.45 μm after the solution was clear and free of impurities.
Preparing a washing buffer solution: 5mL Tween-20, 3mL Proclin300 and 0.3mL RPE2520 were added to 1000mL of phosphate buffer, stirred for more than 30min, and sterile filtered to at least 0.45 μm after the solution was clear and free of impurities.
The foregoing shows and describes the general principles and broad features of the present invention and advantages thereof. It will be understood by those skilled in the art that the present invention is not limited to the embodiments described above, and that various changes and modifications may be made without departing from the spirit and scope of the invention as defined in the appended claims. The scope of the invention is defined by the appended claims and equivalents thereof.
Claims (5)
1. An Alzheimer's disease detection kit based on a magnetic particle luminescence method is characterized by comprising: (1) a plurality of sealed reagent bottles which are respectively filled with capture microsphere mixed liquor, detection antibody, SA-PE, experiment buffer solution, washing buffer solution and working solution, and (2) a kit which separates and integrally packages the reagent bottles; the microbeads are polystyrene microspheres with uniform size, and the polystyrene microspheres are dyed and numbered by different fluorescent dyes, so that microbeads with different codes are obtained; the capture microsphere mixed solution contains protein detection microbeads, and the method specifically comprises the following steps:
the detection micro-bead is formed by respectively coating two antibodies of Abeta 1-42 and p-tau-181 on the surfaces of micro-beads with different codes.
2. The kit for detecting Alzheimer's disease according to claim 1, wherein the diameter of said beads is 5-7 μm.
3. The kit for detecting Alzheimer's disease based on magnetic particle luminescence method of claim 1, wherein the fluorescent marker is phycoerythrin-labeled streptavidin.
4. The Alzheimer's disease detection kit based on the magnetic particle luminescence method of claim 1, wherein the preparation method of the capture microsphere mixture comprises the following steps: and respectively coating different Alzheimer antibodies with microbeads with different codes, and mixing to prepare detection microbeads to obtain the capture microsphere mixed solution.
5. The Alzheimer's disease detection kit based on the magnetic particle luminescence method of claim 1, wherein the detection beads are prepared by the following method: preparing a microbead activating solution, adding any one of the Alzheimer's antibodies according to the proportion that each milliliter of microbead contains 10-100ug of the antibody, fully mixing, coating different Alzheimer's antibodies, and using microbeads with different codes; the microbead activating solution is prepared by adding microbeads of 1000 unit volumes into a reaction tube, and adding 1-ethyl- (3-dimethylaminopropyl) carbodiimide hydrochloride of 5-50 unit volumes and N-hydroxy thiosuccinimide of 5-50 unit volumes for activation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111241752.3A CN114113627A (en) | 2021-10-25 | 2021-10-25 | Alzheimer's disease detection kit based on magnetic particle luminescence method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111241752.3A CN114113627A (en) | 2021-10-25 | 2021-10-25 | Alzheimer's disease detection kit based on magnetic particle luminescence method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114113627A true CN114113627A (en) | 2022-03-01 |
Family
ID=80376659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111241752.3A Pending CN114113627A (en) | 2021-10-25 | 2021-10-25 | Alzheimer's disease detection kit based on magnetic particle luminescence method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114113627A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060014209A1 (en) * | 2004-07-13 | 2006-01-19 | Khalid Iqbal | Method for differentiation of Alzheimer's disease into subgroups |
| CN101246164A (en) * | 2008-01-29 | 2008-08-20 | 广州益善生物技术有限公司 | Alzheimer''s disease early diagnosis liquid phase chip and method for producing the same |
| KR101547058B1 (en) * | 2014-02-24 | 2015-08-25 | 순천대학교 산학협력단 | Microsphere bead and Method for determination of protein using microsphere bead |
| CN109001468A (en) * | 2018-08-06 | 2018-12-14 | 滴准生物科技（常州）有限公司 | A kind of detection kit of CMV antibody IgM |
| CN112798781A (en) * | 2020-12-30 | 2021-05-14 | 北京联众泰克科技有限公司 | Composition for detecting human epididymis protein 4, application of composition, magnetic microsphere electrochemiluminescence immunoassay kit and detection method |
-
2021
- 2021-10-25 CN CN202111241752.3A patent/CN114113627A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060014209A1 (en) * | 2004-07-13 | 2006-01-19 | Khalid Iqbal | Method for differentiation of Alzheimer's disease into subgroups |
| CN101246164A (en) * | 2008-01-29 | 2008-08-20 | 广州益善生物技术有限公司 | Alzheimer''s disease early diagnosis liquid phase chip and method for producing the same |
| KR101547058B1 (en) * | 2014-02-24 | 2015-08-25 | 순천대학교 산학협력단 | Microsphere bead and Method for determination of protein using microsphere bead |
| CN109001468A (en) * | 2018-08-06 | 2018-12-14 | 滴准生物科技（常州）有限公司 | A kind of detection kit of CMV antibody IgM |
| CN112798781A (en) * | 2020-12-30 | 2021-05-14 | 北京联众泰克科技有限公司 | Composition for detecting human epididymis protein 4, application of composition, magnetic microsphere electrochemiluminescence immunoassay kit and detection method |
Non-Patent Citations (1)
| Title |
|---|
| 刘海波;常虹;鲜尽红;文钢;张孟斌;杨黎;: "磁微粒化学发光检测HBsAg试剂盒的研制及其临床应用", 重庆医学, no. 09, 15 May 2008 (2008-05-15), pages 981 - 982 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108362688B (en) | Detection kit for chemiluminescence of 25-hydroxy vitamin D magnetic particles | |
| JP4293904B2 (en) | Method for producing fine particles loaded with protein | |
| CN105548565A (en) | Kit for detecting trypanosoma cruzi antibody as well as preparation and application thereof | |
| CN114113626A (en) | Cytokine detection kit based on magnetic particle luminescence method | |
| CN103898203B (en) | The detection method of Cryptosporidum parvum and detection kit | |
| CN110004148A (en) | Rod method phenol aptamers affinity column and the preparation method and application thereof | |
| CN101539576A (en) | Hepatitis B virus pre S1 antigen chemiluminscence immunoassay kit and preparation method thereof | |
| CN111521780B (en) | Kit for combined detection of hepatitis C virus antigen and antibody and application thereof | |
| CN116500279A (en) | Detection kit for cytomegalovirus antibody IgM and application | |
| CN109444401A (en) | A kind of preparation method of magnetic microparticle chemiluminescence product | |
| CN114113627A (en) | Alzheimer's disease detection kit based on magnetic particle luminescence method | |
| CN108303530B (en) | Porcine pseudorabies gB antibody detection kit and detection method thereof | |
| CN108303541B (en) | Porcine circovirus type 2 antibody detection kit and detection method thereof | |
| CN114113590A (en) | Mycoplasma pneumoniae and chlamydia antibody detection kit based on magnetic particle luminescence method | |
| CN104111333A (en) | Fast erythrocyte removal method applicable to whole blood detection | |
| CN114113589A (en) | Chlamydia trachomatis and mycoplasma urealyticum antigen detection kit based on magnetic particle luminescence method | |
| CN108303540B (en) | Porcine pseudorabies gE antibody detection kit and detection method thereof | |
| CN108303543B (en) | Swine fever E2 protein antibody detection kit and detection method thereof | |
| CN108303531B (en) | O-type foot-and-mouth disease antibody detection kit and detection method thereof | |
| CN105181956B (en) | Application of the fluorescence detection specifically responded based on metal ion in immune detection | |
| CN108303542B (en) | Pig breeding and respiratory syndrome antibody detection kit and detection method thereof | |
| CN115356477A (en) | Streptavidin magnetic bead and preparation method and application thereof | |
| CN113391065A (en) | Receptor reagent for detecting novel coronavirus and application thereof | |
| CN109541231A (en) | A kind of detection antibody of HCV kit and preparation method thereof | |
| CN113391066A (en) | Kit for detecting novel coronavirus antibody and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |